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Treatment with cetuximab, an EGFR-targeting IgG1 mAb, results in beneficial, yet limited, clinical improve-
ment for patients with head and neck (HN) cancer as well as colorectal cancer (CRC) patients with WT KRAS 
tumors. Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells contributes to the efficacy of 
cetuximab. The costimulatory molecule CD137 (4-1BB) is expressed following NK and memory T cell activa-
tion. We found that isolated human NK cells substantially increased expression of CD137 when exposed to 
cetuximab-coated, EGFR-expressing HN and CRC cell lines. Furthermore, activation of CD137 with an ago-
nistic mAb enhanced NK cell degranulation and cytotoxicity. In multiple murine xenograft models, includ-
ing EGFR-expressing cancer cells, HN cells, and KRAS-WT and KRAS-mutant CRC, combined cetuximab and 
anti-CD137 mAb administration was synergistic and led to complete tumor resolution and prolonged survival, 
which was dependent on the presence of NK cells. In patients receiving cetuximab, the level of CD137 on cir-
culating and intratumoral NK cells was dependent on postcetuximab time and host FcyRIIIa polymorphism. 
Interestingly, the increase in CD137-expressing NK cells directly correlated to an increase in EGFR-specific 
CD8+ T cells. These results support development of a sequential antibody approach against EGFR-expressing 
malignancies that first targets the tumor and then the host immune system.
Introduction
Colorectal carcinoma (CRC) is estimated to remain the third most 
common cancer, affecting over 140,000 lives and leading to over 
50,000 deaths in the United States in 2013 alone. Though cases of 
head and neck (HN) cancer are 3-fold less common, the incidence 
continues to rise due to a growing population infected with human 
papillomavirus (HPV) (1). EGFR ERBB1 (avian erythroblastic leu-
kemia viral [v-erb-b] oncogene homolog, receptor for EGF) is a poor 
prognostic marker in multiple solid tumors, including CRC, HN, 
non–small cell lung, and pancreatic carcinomas, and is a therapeu-
tic target of mAbs (cetuximab and panitumumab) as well as small 
molecule kinase inhibitors (erlotinib and gefitinib). Cetuximab, 
a human-mouse chimeric IgG1 mAb, was approved by the Food 
and Drug Administration first in 2004 and today is indicated for 
patients with CRC and HN carcinomas (2). However, responses 
to cetuximab monotherapy are limited; only 1 in 5 patients with 
metastatic CRC (3) and only 1 in 10 with advanced HN carcino-
ma respond to treatment (4, 5). Despite expression of the target, 
patients with non–small cell lung, pancreatic, and CRC with codon 
11 or 12 KRAS mutations fail to benefit from cetuximab (6).
Given multiple mechanisms of cetuximab’s action, a variety of 
approaches have been pursued to enhance its efficacy. By competi-
tively blocking the binding of EGF, phosphorylation and kinase 
activation are prevented, thereby inhibiting cell growth, inducing 
apoptosis, and decreasing production of matrix metalloproteinase 
and vascular endothelial growth factor (7, 8). In addition to these 
in vitro effects, in vivo evidence in both murine models and patients 
suggests cetuximab’s efficacy is due to antibody-dependent cell-
mediated cytotoxicity (ADCC), which requires immune effector 
cells, mainly NK cells, binding via their Fc receptor (FcγRIII, CD16) 
to the IgG1 Fc, heavy-chain, portion of cetuximab (9–13). Targeting 
EGFR by small molecules that lack an Fc, and therefore lack ADCC, 
has not resulted in a clinical benefit in HN or CRCs. Supporting 
ADCC as a primary mechanism of cetuximab’s activity in patients, 
NK cell infiltrate within primary colorectal tumors independently 
predicts prognosis (14). Patients with colorectal and HN carcino-
mas harboring a high-affinity FcγRIII polymorphism have been 
shown to respond more favorably to cetuximab both ex vivo with 
higher cytotoxicity against EGFR-expressing cell lines (15) and clin-
ically with superior disease-free and overall survival (15–19). There-
fore, methods to enhance ADCC, such as stimulating the innate 
immune response, may clinically translate to improved antitumor 
activity. Augmenting the NK cell response to cetuximab therapy 
may enhance the adaptive immune response in addition to innate 
immunity due to NK cell–DC “crosstalk,” which leads to tumor 
antigen–specific T cell responses following cetuximab therapy (20).
We sought to identify an inducible and targetable costimula-
tory molecule on NK cells in order to enhance ADCC. CD137 
(4-1BB) is upregulated on human NK cells when they encounter 
antibody-bound tumor cells (21). Therefore, we hypothesized that 
the antitumor efficacy of cetuximab could be improved through 
a dual antibody strategy: first by inducing CD137 expression on 
NK cells upon their exposure to cetuximab-bound tumor cells 
and subsequently by targeting activated NK cells with an agonis-
tic anti-CD137 mAb.
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Results
Cetuximab induces CD137 upregulation on human NK cells following 
incubation with EGFR-positive tumor cells. CD137 expression was 
induced on the surface of NK cells from healthy human subjects 
following incubation with cetuximab and EGFR-expressing can-
cer cell lines (SCC6, PC1, and SCC4) (Figure 1A). This CD137 
upregulation required the presence of both an EGFR-expressing 
cell and an EGFR-targeting mAb, as little effect on CD137 expres-
sion was observed with cetuximab or with EGFR-expressing can-
cer cell lines alone. Similarly, NK cell expression of CD137 did 
not increase following culture with a non-EGFR–targeting mAb, 
rituximab, which targets CD20, even in the presence of the EGFR-
expressing cells (Figure 1, B and C). The induction of CD137 
occurred preferentially in CD56dim compared with CD56hi NK cells 
and among this subset was associated with a concurrent decrease 
in the expression of the FcγRIII (CD16) (Figure 1, A–C).
Anti-CD137 agonistic mAb increases cetuximab-mediated NK cell 
cytotoxicity on tumor cells and DC cytokine secretion. To determine 
whether CD137 is a potential therapeutic target for enhancing NK 
cell function, NK cells were first activated to express CD137 by their 
exposure to EGFR-expressing cancer cells and cetuximab. Activated 
CD137-expressing NK cells were then reisolated and tested for their 
ability to perform ADCC against EGFR-expressing cancer cells (Fig-
ure 2, A–F). Activated NK cells showed enhanced ADCC following 
anti-CD137 mAb stimulation, as measured by apoptosis (Figure 2, 
A–C) and chromium release (Figure 2, D–F) from EGFR-expressing 
cancer cells. Though the anti-CD137 mAb enhanced cytotoxicity, 
specifically ADCC, enhanced IFN-γ secretion, another usual mea-
sure of NK cell function, in contrast, was not observed (Supple-
mental Figure 1, A–C; supplemental material available online with 
this article; doi:10.1172/JCI73014DS1). However, in the presence 
of activated NK cells, EGFR-expressing cancer cells, cetuximab, and 
immature DCs (iDCs), anti-CD137 agonistic mAb enhanced secre-
tion of IL-12, IFN-γ, and TNF-α (Supplemental Figure 1, D–F).
Anti-CD137 agonistic mAb enhances antitumor activity of cetuximab in 
vivo against both KRAS-mutant and KRAS-WT tumors. We tested the 
ability of cetuximab to induce CD137 expression on murine NK 
cells in vivo in an EGFR-expressing xenotransplant model (SCC6). 
We administered cetuximab 21 days following implantation of 
tumor and measured the expression of CD137 on NK cells in the 
peripheral blood, spleen, and tumor (Figure 3A). In each of the 3 
compartments and at several time points, we observed upregulated 
expression of CD137 on NK cells (Figure 3, B and C). Interestingly, 
at the tumor site, CD137 expression peaked at 24 hours following 
Figure 1
Cetuximab induces CD137 upregulation on human NK cells following incubation with EGFR-positive tumor cells. Peripheral blood from healthy 
donors was analyzed for CD137 expression on CD3–CD56+ NK cells after 24-hour culture with EGFR-positive tumor cell lines SCC6, PC1, and 
SCC4, and cetuximab or rituximab. (A) Percentage of NK cells divided by quadrant to delineate subsets of CD3–CD56bright and CD3–CD56dim 
expressing CD137 from a representative healthy donor after 24-hour culture with the EGFR-positive tumor cell line PC1 and cetuximab. (B) 
Percentage of CD137 expression on NK cells from 3 healthy donors after 24-hour culture with the EGFR-positive tumor cell line SCC6, PC1, or 
SCC4, and cetuximab or rituximab. (C) CD16 expression on NK cells from a 3 healthy donors after 24-hour culture with the EGFR-positive tumor 
cell line SCC6, PC1, or SCC4, and cetuximab or rituximab. *P < 0.001.
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cetuximab and persisted for as long as 1 week following treatment. 
Induced expression at the tumor site was greater at all time points 
compared with that in the spleen or peripheral blood. CD137 
expression peaked in the spleen and peripheral blood at 72 hours 
and returned to baseline by 1 week.
Based on this temporal pattern of CD137 upregulation, anti-
CD137 agonistic mAb was tested in vivo in the EGFR-expressing 
xenotransplant model (SCC6) in combination with cetuximab 
administered concurrently or sequentially with a 24-hour delay. 
Since athymic mice lack functional T cells, this model focused on 
the innate response to the combination of mAbs. A schedule of 
anti-CD137 mAb given once weekly for 4 weeks had no effect on 
tumor growth or survival, cetuximab alone had a modest effect, 
and combination cetuximab and anti-CD137 mAb inhibited 
tumor growth and prolonged survival (Figure 4, A–C). Sequen-
tial, cetuximab followed by anti-CD137 mAb with a 24-hour delay 
Figure 2
Anti-CD137 agonistic mAb increases cetuximab-mediated NK cell cytotoxicity on tumor cells. To evaluate NK cell function, purified NK cells 
were isolated from 3 independent, healthy donor PBMCs and cultured for 24 hours together with cetuximab (10 μg/ml) and irradiated (50 Gy) 
EGFR-expressing cancer cells (PC1) at a ratio of 1:1. After 24 hours, NK cells were isolated by negative selection and assessed for purity (>90% 
purity as defined by CD3–CD56+ flow cytometry) and activation (>50% expression of CD137). EGFR-expressing cancer cell lines including SCC6 
(A and D), PC1 (B and E), and SCC4 (C and F) were cultured for 18 hours with preactivated, purified NK cells in medium alone or with anti-CD137 
mAb (BMS-663513, 10 μg/ml) alone, cetuximab (10 μg/ml) alone, or cetuximab plus anti-CD137 mAbs (both at 10 μg/ml). Cells were washed 
and incubated with annexin V and 7-AAD to determine percentage of apoptotic tumor cells by annexin V and 7-AAD staining. Chromium-labeled 
EGFR-expressing cancer cell lines were cultured for 4 hours with preactivated, purified NK cells in medium alone or with anti-CD137 mAb (BMS-
663513, 10 μg/ml) alone, cetuximab (10 μg/ml) alone, or cetuximab plus anti-CD137 mAbs. Shown is percentage lysis of target cells by chromium 
release at varying effector (activated NK cells)/target cell ratios cultured with medium alone (circles), anti-CD137 (upside-down triangle), cetux-
imab (triangle), or cetuximab and anti-CD137 (square) antibodies. *P = 0.002, SCC6 (A); *P = 0.007, PC1 (B); *P = 0.00 7, SCC4 (C); *P = 0.021, 
SCC6 (D); *P = 0.011, PC1 (E); *P = 0.049, SCC4 (F).
Downloaded on July  9, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/73014
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 6   June 2014 2671
was superior to concurrent combination dosing in effect on both 
tumor growth and survival. This therapeutic schema was tested on 
both KRAS-WT (T84) and KRAS-mutant (HCT116 G13D) tumors 
and demonstrated a similar therapeutic benefit to the sequential 
combination of cetuximab followed by anti-CD137 mAb, with 
near complete tumor regression and all animals surviving 100 days 
after tumor implantation (Figure 4, D–F).
Enhancement of the antitumor activity of cetuximab by anti-CD137 
agonistic mAb is dependent on NK cells and CD8+ T cells. The efficacy 
we observed with combination cetuximab and anti-CD137 mAb 
therapy in athymic mice strongly implicates the innate immune 
system in the mechanism of action. In order to determine whether 
the adaptive immune response also plays a role, we applied the 
combination therapy to a syngeneic tumor model in immuno-
competent BALB/c mice, using a tumor cell line, TUBO, trans-
fected with human EGFR, previously determined to be sensitive 
to cetuximab treatment (Figure 5A and ref. 22). This cell line is 
HER2/neu-dependent and derived from BALB/c mice transgenic 
for the neu oncogene. In this model, anti-CD 137 mAb therapy 
alone had no effect on tumor growth and cetuximab monothera-
py significantly slowed tumor growth, while the sequential com-
bination of cetuximab followed by anti-CD137 mAb led to tumor 
regression and improved survival, with all mice in this group alive 
at day 100 (Figure 5, B and C).
Depletion of CD4+ T cells or macrophages had no influence on 
efficacy (Figure 5, D and E). As hypothesized, depletion of NK cells 
almost completely abrogated the therapeutic benefit. But surpris-
ingly, depletion of CD8+ T cells partially reduced the efficacy of the 
Figure 3
Cetuximab mAb induces CD137 expression in vivo. nu/nu mice were inoculated with 1 × 106 SCC6 tumor cells s.c. on the left flank, and cetux-
imab was administered on day 21 after tumor inoculation (A, schema). (B) Representative CD137 expression on CD3–DX5+ cells isolated from 
the spleen or peripheral blood 24 hours following cetuximab treatment or isotype control in non–tumor-bearing mice (n = 3 mice per group). 
(C) Representative CD3–DX5+ cells isolated from the spleen, peripheral blood, or tumor analyzed for CD137 expression 24, 72, or 168 hours fol-
lowing cetuximab treatment or isotype control in tumor-bearing mice (n = 3 mice per group). For B and C, numbers indicate percentage of cells 
above and below upper limit of isotype control.
Downloaded on July  9, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/73014
research article
2672 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 6   June 2014
Figure 4
Anti-CD137 agonistic mAb enhances antitumor activity of cetuximab in vivo against KRAS-mutant and KRAS-WT EGFR-expressing tumors. 
nu/nu mice were inoculated with 1 × 106 SCC6 tumor cells (KRAS-WT) s.c. on the left flank, and cetuximab and/or anti-CD137 mAb was adminis-
tered starting on day 21 after tumor inoculation (A, schema). (B and C) Following tumor inoculation on day 0, mice received either rat IgG control 
on day 21 (circles), cetuximab on day 21 (squares), anti-CD137 antibody on day 22 (diamonds), cetuximab on day 21 and anti-CD137 antibody 
on day 21 (upside-down triangles), or cetuximab on day 21 and anti-CD137 antibody on day 22 (triangles), with each injection repeated weekly 
for a total of 4 injections. Mice (10 per group) were then monitored for tumor growth (B) and overall survival (C). nu/nu mice were inoculated with 
1 × 106 T84 (KRAS-WT) or HCT116 (KRAS-mutant) tumor cells s.c. on the left flank, and cetuximab and/or anti-CD137 mAb was administered 
starting on day 21 after tumor inoculation (D, schema). (E and F) After tumor inoculation, mice inoculated with HCT116 then received either rat 
IgG control on day 21 (black circles) or cetuximab on day 21 and anti-CD137 antibody on day 22 (blue circles), with each injection repeated 
weekly for a total of 4 injections. Mice inoculated with T84 then received either rat IgG control on day 21 (black diamonds) or cetuximab on day 21 
and anti-CD137 antibody on day 22 (red diamonds), with each injection repeated weekly for a total of 4 injections. Mice (10 per group) were then 
monitored for tumor growth (E) and overall survival (F). *P < 0.001.
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combination therapy, suggesting a role for the adaptive immune 
response in addition to dependence on NK cells. To further inves-
tigate adaptive immunity following combination therapy with 
cetuximab and anti-CD137 mAb, we rechallenged cured mice 
with both TUBO and TUBO-EGFR tumor cell lines. Mice previ-
ously cured with cetuximab and anti-CD137 mAb rejected both 
TUBO and TUBO-EGFR (Figure 5, F and G), arguing for epitope 
spreading and a memory T cell response. Recognizing an adaptive 
immune response was present with epitope spreading, we investi-
gated the ability of anti-CD137 mAb to augment the therapeutic 
immune response in a 2-tumor model with TUBO and TUBO-
EGFR tumor cell lines implanted simultaneously on contralateral 
flanks (Figure 6A). Only in mice receiving the combination of 
cetuximab and anti-CD137 mAb did both the TUBO and TUBO-
EGFR tumors regress (Figure 6B). Interestingly, the NK cell and 
DC infiltrate within TUBO-EGFR tumors was greater than within 
TUBO tumors from the same animal; similarly, NK cell and DC 
infiltrate within TUBO-EGFR tumors was significantly greater in 
mice receiving anti-CD137 mAb and cetuximab versus cetuximab 
alone (Figure 6C). A minor but not significant reduction in CD4+ 
T cells was observed in both TUBO and TUBO-EGFR tumors in 
mice receiving the combination versus cetuximab alone. Support-
ing the enhanced adaptive response and potential mechanism for 
antitumor activity against a non-EGFR–expressing tumor, the 
CD8+ T cell infiltrate was less in TUBO or TUBO-EGFR tumors 
from the mice receiving only cetuximab, while in mice receiving 
cetuximab and anti-CD137 mAb, the CD8+ T cell infiltrate was 
greater in both TUBO and TUBO-EGFR tumors. Functionally, 
circulating CD8+ T cells isolated from mice following cetuximab 
and anti-CD137 mAb produced greater IFN-γ ex vivo than CD8+ 
Figure 5
Enhancement of antitumor activity 
of cetuximab by anti-CD137 mAb is 
dependent on NK and CD8+ T cells. 
BALB/c mice were inoculated with 
1 × 106 TUBO-EGFR tumor cells s.c. 
(A, schema). Mice (10 per group) then 
received either rat IgG on day 14 (cir-
cles), cetuximab on day 14 (squares), 
anti-CD137 antibody on day 15 (dia-
monds), or cetuximab on day 14 and 
anti-CD137 antibody on day 15 (trian-
gles), each repeated 4 times weekly, 
with animals monitored for tumor 
growth (B, *P = 0.047) and overall sur-
vival (C, *P < 0.001). After tumor inoc-
ulation, mice (10 per group) received 
either rat IgG on day 14 (circles) or 
cetuximab on day 14 and anti-CD137 
antibody on day 15, with each injection 
repeated weekly for a total of 4 injec-
tions with anti–asialo-GM1 starting on 
day –1 (diamonds), liposomal clodro-
nate starting on day –2 (upside-down 
triangles), anti-CD8 mAb starting on 
day –1 (squares), anti-CD4 mAb start-
ing on day –1 (red circles), or no cell-
depleting mAb (blue triangles); ani-
mals were monitored for tumor growth 
(D, *P < 0.001; **P < 0.008) and overall 
survival (E, *P < 0.001). Naive BALB/c 
mice were inoculated with 1 × 106 
TUBO-EGFR (circles) or 1 × 106 TUBO 
tumor cells (upside-down triangles), 
or BALB/c mice previously (100 days 
prior) inoculated with TUBO-EGFR 
tumor cells and cured with cetuximab 
and anti-CD137 antibody were inocu-
lated with 1 × 106 TUBO-EGFR (blue 
triangles) or 1 × 106 TUBO tumor cells 
(red squares) s.c. and monitored for 
tumor growth (F, *P < 0.001) and over-
all survival (G, *P < 0.001).
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T cells isolated from mice following cetuximab alone (Figure 6D). 
Interestingly, CD8+ T cells produced greater IFN-γ when exposed 
to TUBO tumor cells following cetuximab and anti-CD137 mAb 
therapy compared with cetuximab alone, suggesting anti-CD137 
mAb augments the adaptive CD8+ T cell response with epitope 
spreading beyond EGFR.
To further compare the relative strength of the adaptive immune 
response following cetuximab versus combination cetuximab and 
anti-CD137 mAb therapy, we isolated total and CD8-selected 
splenocytes from mice previously inoculated with TUBO-EGFR 
tumor cells and treated them with either cetuximab monotherapy 
or sequential cetuximab and anti-CD137 mAb combination. As 
measured by the Winn adoptive transfer assay, anti-CD137 mAb 
therapy significantly improved adaptive immunity to both TUBO-
EGFR (Figure 6E) and TUBO (Figure 6F) tumor cells. The major-
ity, 60%–80%, of mice were protected against either tumor by total 
or CD8-selected splenocytes from mice having received combina-
tion therapy compared with 0%, no evidence of protection, follow-
ing transfer of total or CD8-selected splenocytes from mice having 
received cetuximab monotherapy.
Increased expression of CD137 on circulating and tumor-infiltrating NK 
cells and increased frequency of EGFR-tetramer+ CD8+ T cells in patients receiv-
ing cetuximab therapy. We identified 54 patients with HN squamous 
cell carcinomas receiving cetuximab therapy. PBMCs were isolated 
prior to and following the first cetuximab administration, includ-
ing samples obtained every 24 hours for up to 1 week (Figure 7A). 
A decline occurred in the number of circulating NK cells and in 
their expression of the FcγRIII, CD16, concomitant with their 
increased expression of CD137 (Figure 7B). Comparing all pre- to 
postcetuximab peripheral blood samples, a significant increase in 
percentage of NK cells expressing CD137 was observed, 4% to 15% 
(Figure 7C), with persistence of upregulated expression of CD137 
from 24 hours to 1 week following cetuximab (Figure 7D).
We next investigated the possible influence of FcγRIIIA poly-
morphisms on the cetuximab-induced upregulation of CD137 on 
NK cells. A greater increase in CD137 expression was seen among 
patients harboring high-affinity alleles FcγRIIIA-158 (V/V or F/V) 
compared with those with low-affinity FcγRIIIA-158 (F/F) alleles 
(Figure 7E). Finally, we evaluated intratumoral NK cell expression 
of CD137 in patients with HN cancer and observed a significant 
increase following cetuximab (Figure 7F).
Taking our observation of an adaptive component to the 
response to cetuximab and anti-CD137 mAb together with a prior 
report demonstrating induction of EGFR-specific CD8+ T cells fol-
lowing cetuximab (23, 24), we measured antigen-specific CD8+ T 
cells by tetramer analysis. A significant increase in EGFR-specific 
CD8+ T cells was observed approximately 1 week following cetux-
imab among 10 patients with HN cancer (Figure 8, A and B). To 
explore the connection between magnitude of innate and adap-
tive immune response following cetuximab, we tested the correla-
tion between percentage of CD8+ T cells specific for EGFR and 
percentage of NK cells upregulating CD137 in peripheral blood 
in patients following cetuximab therapy. Interestingly, there was a 
highly significant correlation (Figure 8C).
Discussion
Activation of EGFR provides a strong growth signal, resulting in 
tumor proliferation, reduced apoptosis, increased angiogenesis, 
and a poor prognosis for patients with epithelial cancer, including 
CRC, and HN squamous cell as well as pancreatic and non–small 
cell lung cancer (25, 26). Despite extensive study, including 17 ran-
domized trials enrolling nearly 8,000 patients, cetuximab therapy 
confers an improved response rate and progression-free and over-
all survival only in HN carcinoma and in KRAS-WT CRC (6).
Here, we report a method to enhance the efficacy of cetuximab 
therapy. In contrast to efforts to improve the single agent efficacy 
of a mAb, such as by increasing Ab affinity, making versions with 
2 different specificities, conjugation to toxins, or conjugation to 
radio-isotopes, here we propose to augment the immune response 
following administration of the tumor-targeted mAb by using a 
sequential combination of 2 different antibodies. First, cetuximab 
localizes to the site of the tumor and activates surrounding NK 
cells via the Fc-FcγR interaction, thereby increasing NK cell expres-
sion of activation and costimulatory markers, such as CD137. An 
agonistic mAb against CD137 is then administered to enhance the 
activated NK cell’s ability to kill cetuximab-coated tumor cells.
Our findings here with cetuximab are consistent with our results 
in 2 prior models, including rituximab and trastuzumab, target-
ing CD20 and HER2/neu, respectively, underscoring the general 
applicability of this approach (27, 28). Prior literature supports 
that CD137, also known as 4-1BB, is expressed on activated CD4+ 
and CD8+ T cells, and following trimerization on the cell surface, it 
provides a proliferative T cell signal (29). Recently, CD137 expres-
sion has also been reported on monocytes, DCs, and nonhemato-
poietic cells with potential functional importance (30, 31). CD137 
ligand expression, as observed in acute myeloid leukemias, inter-
estingly has been proposed to lead to an inhibitory signal (32) in 
which leukemic blasts have been shown to impair NK cell sponta-
neous cytotoxicity. The function of anti-CD137 mAb could, there-
fore, block an inhibitory signal from the tumor cell to the incom-
ing NK cell in tumors that express the CD137 ligand. Importantly, 
we did not observe CD137 ligand expression on the HN or CRCs 
investigated in this study, arguing against this mechanism for the 
Figure 6
Anti-CD137 mAb enhances adaptive immunity following cetuximab. 
BALB/c mice were inoculated with 1 × 106 TUBO-EGFR (red sym-
bols) s.c. on the left flank and 1 × 106 TUBO tumor cells (black sym-
bols) s.c. on the right flank (A, schema). After tumor inoculation, mice 
(15 per group) then received either rat IgG control on day 14 (circles), 
cetuximab on day 14 (triangles), or cetuximab on day 14 and anti-
CD137 antibody on day 15 (diamonds), with each repeated 4 times 
weekly; animals were monitored for tumor growth (B, *P < 0.001; 
**P = 0.021). On day 24, TUBO and TUBO-EGFR tumors were resect-
ed from 5 untreated (NT, IgG control) mice and mice treated with cetux-
imab monotherapy and combination cetuximab and anti-CD137 mAb; 
animals were analyzed for percentage of total viable cells represent-
ing tumor-infiltrating DCs, NK cells, and CD4+ and CD8+ T cells (C, 
*P < 0.05, **P < 0.01, **P < 0.001). On day 24, PBMCs were collected 
from 5 untreated (black symbols) mice and mice treated with cetux-
imab monotherapy (white symbols) and combination cetuximab and 
anti-CD137 mAb (half-black symbols) and analyzed ex vivo for IFN-γ 
production following exposure to medium (negative control, circles), 
A20 (negative control, squares), TUBO (triangles), or TUBO-EGFR 
(diamonds) cell lines (D, *P = 0.009, **P < 0.001). Splenocytes were 
obtained from naive mice (total splenocytes, circles) or mice sacrificed 
50 days following tumor inoculation and treatment with either cetux-
imab monotherapy (total splenocytes, CD8-selected, upside-down 
triangles) or sequential cetuximab and anti-CD137 mAb (total spleno-
cytes, CD8-selected, triangles) and were coinjected (100:1) into naive 
mice (10 per group) with TUBO (E, *P < 0.001) or TUBO-EGFR (F, 
*P < 0.001) and monitored for percentage of mice that were tumor free.
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occur wherever tumor cells are located, regardless of anatomic site, 
such as within the primary tumor, tumor-involved lymph nodes, 
or at distant sites of metastatic cancer. We did observe activated 
NK cells in circulation of patients as well as in the spleen of mice 
following cetuximab. We presume that these activated NK cells 
had migrated from their initial site of antibody-induced activa-
tion in the tumor. Consistent with this view is our finding that in 
patients, the highest and most prolonged upregulation of CD137 
was noted on intratumoral NK cells.
Despite the predominant role of NK cells and the innate immune 
response underlying the mechanism of synergy, we observed a role 
for CD8+ T cells in the antitumor response. In the combination 
of anti-CD20 mAb followed by anti-CD137 mAb, increased late 
relapses were noted when CD8+ T cells were depleted (45). In the 
current study, CD8+ T cell depletion abrogated the survival benefit 
and reduced the initial antitumor response. Interestingly, however, 
in our rechallenge experiment, we observed protection not only 
against an EGFR-expressing cell line, but also the identical cell line 
without EGFR expression, suggesting epitope spreading occurred 
and antitumor memory developed that was not limited to EGFR. 
In a prior immunocompetent mouse model of lymphoma, tar-
geted by anti-CD20 mAb, protection from rechallenge was dem-
onstrated; however, the model did not allow a determination of 
whether an immune response extended beyond CD20 (46). In fur-
ther support by the Winn assay (47), we observed that anti-CD137 
mAb following cetuximab treatment enhanced adaptive immunity 
with a significantly higher rate of CD8+ T cell–mediated protec-
tion to EGFR-expressing and nonexpressing tumors. The role of 
adaptive immunity and CD8+ T cells may be an on-target effect 
of anti-CD137 mAbs in vivo influencing the function of multiple 
cell types including hematopoietic cells such as granulocytes, T 
cells, B cells, DCs, and monocytes in addition to NK cells, as well 
as nonhematopoietic cells (31, 48–51). Recently, Lee et al. reported 
that tumor-targeting mAbs such as cetuximab induce an adaptive 
tumor antigen–specific T cell response that is primed by NK cell 
activation and subsequent NK cell–DC crosstalk (20). Our in vitro 
observations of enhanced IL-12, IFN-γ, and TNF-α support these 
findings that activated human NK cells increase DC maturation 
and cytokine production in both a cell-contact–dependent, due to 
NKp30, and independent manner that can be further enhanced 
by anti-CD137 mAb stimulation (52, 53). In vivo, the addition of 
anti-CD137 mAb to cetuximab increases recruitment of NK cells 
as well as DCs to EGFR-expressing tumors, augmenting the innate 
immune response locally and secondarily enhancing DC function 
and adaptive immunity with increased local and distant tumor 
infiltration with CD8+ T cells.
The systemic nature of the T cell response observed in the 
mouse model is consistent with findings in the peripheral blood 
of patients with HN carcinoma. Circulating EGFR-specific T cells 
have been identified that have preserved proliferative and cytotoxic 
function as well as a direct correlation with levels of EGFR expres-
sion on the tumor and size of the EGFR-specific T cell population 
(23). Recently, the NK cell–DC interaction has been reported to 
promote cross-presentation of tumor antigen independently of 
NK cell cytotoxicity, (54) and Srivastava et al. connected these find-
ings by identifying enhanced cross-presentation leading to EGFR-
specific T cells following NKG2D/MICA binding and induction of 
DC maturation among patients receiving cetuximab therapy (24). 
Therefore, as our results demonstrate, anti-CD137 mAb stimula-
tion enhances NK cell–DC crosstalk while also directly enhancing 
enhanced NK cell function. Our observation is consistent with 
additional mouse and human studies that report anti-CD137 
enhancement of NK cell killing in both hematopoietic and solid 
tumors lacking expression of the CD137 ligand (33–36). Rather, 
by first activating NK cells via CD16 and the Fc-FcγR interaction, 
surface expression of CD137 is induced and subsequently directly 
stimulated by administering the agonistic anti-CD137 mAb.
Although CD137 stimulation has been shown to enhance NK 
cell function and proliferation in mice (33–36), a recent study sug-
gests that it may have opposite effects on human NK cells, leading 
to decreased function, including cytotoxicity (32). This discrep-
ancy with our current results is likely due to differences in experi-
mental conditions. First, we used freshly isolated NK cells instead 
of NK cells cultured with IL-2 and feeder cells for 10 days. Second, 
we stimulated CD137 using an agonistic antibody as opposed to 
the CD137 ligand (4-1BBL). Finally, we measured enhancement 
of ADCC as opposed to natural spontaneous NK cell cytotoxicity.
To directly implicate NK cells as the main effector cells respon-
sible for augmenting cetuximab, we used purified NK cells for in 
vitro studies. For in vivo studies, we used tumors engrafted into 
nu/nu mice, which have NK cells, macrophages, and complement, 
but lack T cells, and in addition, we used syngenic mouse models 
that were depleted in various cell subsets. NK cell expression of 
CD137 has been observed in prior studies using immobilized IgG1 
or rituximab-coated lymphoma cells (21, 37). Expression occurs 
predominantly among the CD56dim subset of NK cells known to 
mediate ADCC compared with CD56hi NK cells, which are respon-
sible for secretion of cytokines such as IFN-γ (38), explaining our 
result of a lack of increased IFN-γ with anti-CD137 mAb despite 
enhanced ADCC. In the preclinical models and patient samples 
following cetuximab therapy, we observed a concurrent downregu-
lation of CD16 among the CD56dim subset, supporting the inter-
nalization of the FcγR following Fc-FcγR binding (39, 40).
A potential advantage of the combination strategy we pro-
pose is that only the NK cells in contact with cetuximab-bound 
tumor cells will be activated, as opposed to other more general NK 
cell–activating strategies, such as high-dose IL-2, IL-12, or other 
cytokines, which though clinically beneficial, are limited by the 
systemic toxicity (41–44). Our more directed NK activation would 
Figure 7
Increased expression of CD137 on circulating and tumor-infiltrating 
NK cells in patients receiving cetuximab therapy. PBMCs or tumor 
biopsies by fine needle aspirate (FNA) were isolated from 54 patients 
with EGFR-expressing HN carcinoma (A). (B) CD56 and CD3 expres-
sion on circulating lymphocytes and CD16 and CD137 expression 
on NK cell subsets CD3–CD56bright and CD3–CD56dim from a single 
representative patient at 2 time points, including prior to cetuximab 
and 24 hours following cetuximab (number indicates percentage of 
cells as divided by quadrant). (C) Percentage of CD137+ cells among 
circulating CD3–CD56+ NK cells from 54 patients prior to and follow-
ing cetuximab (mean at each time point denoted by bar, *P < 0.001). 
(D) Percentage of CD137+ cells among circulating CD3–CD56+ NK cells 
from 54 patients prior to and following cetuximab stratified by specific 
time after cetuximab infusion (mean at each time point denoted by bar). 
(E) Absolute change in percentage of CD137+ cells among circulating 
CD3–CD56+ NK cells from 54 patients prior to and following cetuximab 
stratified by FcγRIIIA-158 polymorphism (P = 0.011). (F) Percentage 
of CD137+ cells among tumor-infiltrating CD3–CD56+ NK cells from 8 
patients prior to and following cetuximab (1 patient with only precetux-
imab sample and no postcetuximab sample evaluable; P = 0.020).
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The addition of anti-CD137 mAb therapy to cetuximab shows 
promise of improving its efficacy against HN and CRC and also, 
perhaps, extending its efficacy to other EGFR-expressing cancer 
types. KRAS mutations confer increased resistance to the ability of 
cetuximab to block phosphorylation and signal transduction, but 
do not confer resistance to ADCC (58). Therefore, we investigated 
whether the addition of anti-CD137 agonistic mAb stimulation 
could extend cetuximab to KRAS-mutant tumors. We observed 
equal efficacy in reducing tumor growth and prolonging survival 
with the combination of cetuximab and anti-CD137 mAb therapy 
against KRAS-WT and KRAS-mutant tumors. Enhancing ADCC 
with CD137 stimulation may offer the opportunity to overcome 
this important mechanism of tumor resistance.
NK cell and CD8+ T cell function, particularly NK cell cytotoxicity 
and CD8+ T cell production of IFN-γ (20, 55–57). Based on these 
findings, we selected a series of HLA-A2+ patients with HN car-
cinoma and assayed for presence of EGFR-specific CD8+ T cells. 
We observed not only presence and expansion of this population 
following cetuximab treatment, but also a direct correlation, with 
increase in EGFR-specific T cells and increase in CD137 expres-
sion on NK cells. Our results further support the tight interplay 
between the innate and adaptive immune response following 
cetuximab therapy. We hypothesize that anti-CD137 agonistic 
mAb therapy may both stimulate ADCC due to cetuximab-acti-
vated NK cells and promote the proliferation and cytotoxicity of 
EGFR-specific T cells induced by cetuximab treatment.
Figure 8
Increased frequency of EGFR-tetramer+ CD8+ T cells in patients receiving cetuximab therapy. (A) HIV-tetramer–specific or EGFR-tetramer–spe-
cific (YLN) CD8+ T cells from 2 healthy controls and 2 representative patients with HN cancer prior to and 7 or 5 days following cetuximab therapy 
(number indicates percentage of cells as divided by quadrant). (B) Percentage of EGFR-tetramer–specific CD8+ T cells from 10 patients with HN 
cancer prior to and 5 to 7 days following cetuximab therapy. (C) Correlation of absolute change in percentage of CD137+ cells among circulating 
CD3–CD56+ NK cells and absolute change in percentage of EGFR-tetramer–specific CD8+ T cells from 10 patients with HN cancer prior to and 
following cetuximab therapy (R2 = 0.87, P = 0.001).
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with 10% heat-inactivated FCS (HyClone Laboratories), 2% l-glutamine, 
1% penicillin, and 1% streptomycin (all from Invitrogen Life Technologies). 
The HCT116 cancer cell line was cultured in DMEM medium (Invitrogen 
Life Technologies) supplemented as above. The TUBO-EGFR cancer cell 
line was cultured in DMEM supplemented with 10% FCS, 10 mM Hepes, 
1% nonessential amino acids, 1% penicillin, and 1% streptomycin (all from 
Invitrogen Life Technologies). The A20 cell line was cultured in RPMI 
1640 medium supplemented with 10% heat-inactivated FCS (HyClone 
Laboratories), 2% l-glutamine, 1% penicillin, and 1% streptomycin (all from 
Invitrogen Life Technologies) and 50 μM 2-ME (Gibco; Invitrogen). Cells 
were grown as adherent cultures at 37°C in 5% CO2 and passaged after 
detachment by 0.05% trypsin (Invitrogen Life Technologies). SCC6, PC1, 
SCC4, T84, HCT116, and TUBO-EGFR express moderate to high levels of 
EGFR with specific fluorescence indices (tumor MFI/isotype MFI) of 17.2, 
18.1, 53.1, 55.2, 56.1, and 63.3. These cell lines express neither the CD137 
ligand nor the CD137 receptor.
Mice. Five- to six-week-old female athymic (nu/nu) nude-Foxn1nu and 
BALB/C mice were purchased from Harlan and Jackson Laboratories and 
were housed at the Laboratory Animal Facility at Stanford University 
Medical Center.
Therapeutic antibodies. Rat anti-mouse CD137 (4-1BB) mAb (IgG2a, clone 
2A; ref. 59) was produced from ascites in SCID mice as previously described 
(31, 45). Control rat IgG was obtained from Sigma-Aldrich. Human anti-
human CD137 mAb (BMS-663513, IgG4) was provided by Bristol-Myers 
Squibb. Rituximab (murine-human chimeric anti-CD20, IgG1) and cetux-
imab (murine-human chimeric anti-EGFR, IgG1) were obtained from 
Genentech and Bristol-Myers Squibb.
CD137 expression on human NK cells and EGFR-tetramer+ CD8+ T cells from 
patient samples and healthy individuals. PBMCs were isolated from patients 
with HN cancer at multiple time points and from healthy donors obtained 
from the Stanford Blood Center by density gradient separation using 
Ficoll-Paque Plus (Amersham Biosciences). PBMCs from patients with 
HN cancer at time points including immediately prior to and either 24, 
48, 72, 96, 120, 144, or 168 hours after cetuximab infusion were assayed 
for NK cell expression of CD137 and CD16 as well as EGFR-tetramer, HIV-
tetramer, and CD8 in a subset of patients. PBMCs isolated from healthy 
individuals or purified NK cells isolated by negative magnetic cell sorting 
using NK cell isolation beads (Miltenyi Biotec) were cultured at a ratio of 
1:1 in complete medium for 24 hours with breast cancer cell lines in the 
presence of rituximab (10 μg/ml) or cetuximab (10 μg/ml). Assessment of 
CD137 and CD16 expression on NK cells was performed in triplicate for 
each of 3 healthy individuals.
In vitro NK functional assays. PBMCs or purified NK cells were incubated 
for 24 hours with irradiated (50 Gy) EGFR-expressing cancer cells (SCC6, 
PC1, or SCC4) at a ratio of 1:1 and with cetuximab (10 μg/ml). Follow-
ing 24-hour culture of PBMCs with irradiated cancer cells, purified NK 
cells were then isolated by negative magnetic cell sorting using NK cell 
isolation beads (Miltenyi Biotec), according to the manufacturer’s instruc-
tions, at more than 90% purity, as defined by CD3–CD56+, confirmed by 
flow cytometry. Activation of NK cells was confirmed by flow cytometry 
(>50% expression of CD137). The activated NK cells were then cultured 
with additional EGFR-expressing cancer cell lines (SCC6, PC1, or SCC4) 
at a ratio of 1:1. After 18 hours, the supernatants were removed and 
assayed for IFN-γ by ELISA (Human Interferon-γ BD OptEIA ELISA Set 
and BD OptEIA Reagent Set B; BD Biosciences — Pharmingen). Cells from 
these cultures were incubated with FITC–annexin V and 7-AAD (both BD 
Biosciences) and analyzed by flow cytometry. Forward and side scatter 
were used to gate out the NK cells, and fluorescence was used to deter-
mine the percentage of apoptotic tumor cells by annexin V and 7-AAD 
staining. NK cell cytotoxicity was additionally measured by a chromium 
We have studied patients with HN carcinoma receiving thera-
py with cetuximab. We found NK cells in circulation and in the 
tumors that have upregulated CD137. We have also found that 
FcγRIII polymorphisms correlate with the magnitude of CD137 
upregulation, with increased CD137 associated with the high-
affinity alleles. We observed a significant increase in NK cell 
CD137 expression following cetuximab occurring within 24 hours; 
in some patients, it was elevated as long as 1 week. The increased 
expression in the peripheral blood and within the tumor was het-
erogeneous, with a subset of patients demonstrating minimal 
upregulation. Though the ongoing and planned phase I and I/II 
clinical trials do not limit enrollment based on CD137 expres-
sion, we speculate that patients with minimal upregulation of 
CD137 may not benefit from anti-CD137 mAb therapy. To iden-
tify predictors of CD137 upregulation, the FcγRIII polymorphism 
of all patients was typed and stratified by presence of a single 
high-affinity allele. Patients with HN cancer with either V/V or 
V/F demonstrated greater CD137 upregulation compared with 
patients with 2 low-affinity alleles. With continued enrollment in 
this phase 0 study, we will identify clinical and pathologic char-
acteristics that predict the heterogeneity in CD137 upregulation. 
By doing so, we hope to create a nomogram predictive of CD137 
expression, which with validation in ongoing clinical trials and 
correlation with clinical response to anti-CD137 mAb therapy, 
may provide a predictive biomarker for patient selection and indi-
vidually tailored treatment schedules.
By changing the paradigm of improving antibody technology — 
not by creating superior tumor-targeting mAbs, rather by target-
ing the secondary immune response — we have identified a thera-
peutic strategy that is selective to the tumor microenvironment 
and efficacious in multiple models, including those resistant to 
treatment. The approach is dependent upon sequential target-
ing of first, the tumor, by cetuximab, and second, the activated 
NK cells, by anti-CD137 agonistic mAbs. This strategy initiates 
a more robust innate immune response with augmented ADCC 
as well as adaptive immunity through likely enhanced crosstalk 
between NK cells, DCs, and tumor antigen–specific CD8+ T cells. 
By investigating predictors of CD137 expression, such as FcγRIII 
polymorphism, in patients receiving cetuximab monotherapy, we 
hope to identify biomarkers that will be tested along with the cen-
tral hypothesis of this new strategy in a planned combination trial 
with an anti-CD137 agonistic antibody.
Methods
Cell lines and culture. The human EGFR-expressing cancer cell lines SCC4, 
SCC6, and PC1 were obtained from John Sunwoo at Stanford University. 
SCC4 is an upper aerodigestive tract squamous cell carcinoma with muta-
tions in CDKN2A, NF1, and TP53 and WT KRAS, EGFR, MET, NRAS, and 
PTEN. SCC6 is an upper aerodigestive tract squamous cell carcinoma with 
mutations in CDKN2A and WT NF1, TP53, KRAS, EGFR, ET, NRAS, and 
PTEN. PC1 is a pancreatic adenocarcinoma with mutations in CDKN2A, 
KRAS (G12D), and TP53 and WT EGFR, NRAS, MET, NF1, and PTEN. 
Human EGFR-positive cancer cell lines T84 (KRAS-WT), HCT116 (KRAS 
G13D mutant), and A20 (a lymphoma cell line used as a negative control) 
were obtained from ATCC. T84 is a CRC with mutations in APC and TP53 
and WT NF1, KRAS, NRAS, MET, PTEN, and EGFR. HCT116 is a CRC with 
mutations in KRAS (G13D), APC, and TP53 and WT NF1, NRAS, MET, 
PTEN, and EGFR. The TUBO-EGFR murine cancer cell line was obtained 
from Yang-Xin Fu at the University of Chicago. The SCC4, SCC6, PC1, and 
T84 cell lines were cultured in a 1:1 mixture of DMEM:F12 supplemented 
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precipitate red cells. Leukocyte-containing supernatant was removed and 
centrifuged, and the remaining red cells were lysed with ACK Lysis Buffer 
(Quality Biological). Splenocytes and subcutaneous tumors from 3 mice 
per treatment group were resected 24, 72, or 168 hours following cetux-
imab treatment or isotype control in tumor-bearing mice and mechani-
cally digested into a single-cell suspension. Cells were stained with mAbs 
to evaluate CD137 expression on NK cells by CD3–DX5+ expression by flow 
cytometry. Subcutaneous TUBO and TUBO-EGFR tumors from 5 mice 
per treatment group were resected on day 24 after tumor inoculation and 
analyzed for NK cell, T cell, and DC infiltration by flow cytometry of a 
single-cell suspension following mechanical digestion. The tumor-infil-
trating DC population was marked by CD11c+ and high surface expres-
sion of MHC class I and class II proteins with expression of costimula-
tory molecules CD80 (B7.1) and CD86 (B7.2). PBMCs collected on day 24 
after tumor inoculation from 5 mice per group in the 2 tumor model were 
purified as described and then cocultured with medium, 1 × 106 irradiated 
A20, TUBO, or TUBO-EGFR cells for 24 hours with 0.5 mg anti-mouse 
CD28 mAb (BD Biosciences — Pharmingen) and in the presence of monen-
sin (Golgistop; BD Biosciences) for the last 5 hours at 37°C and 5% CO2. 
Intracellular IFN-γ expression was assessed with BD Cytofix/Cytoperm 
Plus Kit per instructions.
Depletion of CD4+ and CD8+ T cells, NK cells, and macrophages. Anti-CD4 
mAb, anti-CD8 mAb, anti-asialo GM1 mAb (Wako Chemicals), and lipo-
somal clodronate (Weissman laboratory, Stanford University) were used to 
deplete CD4+ T cell, CD8+ T cell, NK cell, and macrophage activity in vivo, 
respectively. Ascitic fluid was harvested from SCID mice bearing hybrid-
omas GK1.5- and GK2.43-producing anti-CD4 (rat IgG2b) and anti-CD8 
(rat IgG2b) mAbs. The ascites were diluted in sterile PBS. Depleting anti-
CD4 mAb, anti-CD8 mAb, and anti-asialo GM1 mAb were injected i.p. on 
day –1 and day 0 of tumor inoculation, and every 5 days thereafter until 
day 45 at a dose of 500 μg per injection of anti-CD4 mAb or anti-CD8 mAb 
and 50 μl per injection of anti-asialo GM1 mAb. Liposomal clodronate was 
injected retroorbitally on day –2 at a dose of 200 μl and on day 0 of tumor 
inoculation, followed by every 4 days until day 44 at a dose of 100 μl per 
injection. The depletion conditions were validated by flow cytometry of 
blood showing more than 95% depletion of each cell subset.
Antibodies for flow cytometry. mAbs to human antigens were used for stain-
ing of human PBMCs including the following: CD16 FITC, CD4 FITC, 
CD8 FITC, CD137 ligand PE, CD56 PE, CD3 PerCP, anti-EGFR APC, 
CD137 APC, APC-H7, FITC–annexin V, and 7-AAD (all from BD). HIV-
tetramer PE and EGFR-tetramer (YLN) PE were provided by the NIH Tet-
ramer Core Facility (Atlanta, Georgia, USA) as well as Mark Davis (Stan-
ford University). The following mAbs to mouse antigens were used: CD8 
FITC (BD), CD4 FITC (BD), CD137 ligand PE (eBioscience), CD137 PE 
(eBioscience), CD3 PerCP (BD), DX5 APC (eBioscience), CD11c-PE (BD), 
MHC I APC (BD), MHC II APC (BD), B7.1 APC (BD), B7.2 FITC (BD), and 
F4/80 APC (eBioscience). Stained cells were collected on a FACSCalibur or 
a LSRII 3-laser cytometer (BD), and data were analyzed using Cytobank 
(http://www.cytobank.org) (61).
Analysis of FcγRIIIa polymorphisms. Genomic DNA was prepared from 
peripheral blood mononuclear cells using a DNA extraction kit (QIAGEN). 
Genotyping of FcγRIIIa 158 V/F polymorphism was performed by a poly-
merase chain reaction followed by allele-specific restriction enzyme diges-
tion (62). All genotyping of FcγRIIIa polymorphism was confirmed by 
direct sequencing of the region of interest.
Statistics. Prism software (GraphPad) was used to analyze tumor growth 
and comparison of cell populations to determine statistical significance of 
differences (data presented as mean ± SEM) between groups by applying a 
2-tailed, unpaired Student’s t test or 2-way ANOVA with Bonferroni’s cor-
rection for multiple comparisons. Kaplan-Meier plots were used to analyze 
release assay (60): target tumor cells were labeled with 150 μCi 51Cr per 
1 × 106 cells for 2 hours. Activated, purified, and nonpurified NK cells 
were prepared as described above and were then added at variable effec-
tor/target cell ratios from 1:1 to 50:1. Percentage of lysis was determined 
after 4 hours of culture in the presence of anti-CD137 mAb (BMS-663513, 
10 μg/ml) alone, cetuximab (10 μg/ml) alone, or cetuximab plus anti-
CD137 mAbs (both at 10 μg/ml). All assays were performed in triplicate 
with 3 independent NK cell samples.
In vitro DC functional assays. Autologous iDCs were prepared as previ-
ously described (52). iDC populations were checked for CD1a and CD80 
expression and lack of CD14 expression. Activated and purified NK cells 
were prepared as described above. Activation of NK cells was confirmed 
by flow cytometry (>50% expression of CD137). The activated NK cells 
were then cultured with autologous iDCs and EGFR-expressing cancer 
cell lines (SCC6, PC1, or SCC4) at a ratio of 1:1:1 for 18 hours in medium 
alone or with anti-CD137 mAb (BMS-663513, 10 μg/ml) alone, cetuximab 
(10 μg/ml) alone, or cetuximab plus anti-CD137 mAbs (both at 10 μg/ml); 
supernatant was harvested and analyzed by ELISA for IFN-γ, IL-12 p40, 
and TNF-α (human IFN-γ, IL-12 p40, and TNR-α BD OptEIA ELISA Sets 
and BD OptEIA Reagent Set B; BD Pharmingen). All assays were performed 
in triplicate with 3 independent NK:iDC cell samples.
Tumor transplantation and antibody therapy. SCC6 cancer cells were 
implanted s.c. into 5- to 6-week-old female athymic nu/nu mice at a dose 
of 1 × 106 cells in 50 μl of PBS (BD Biosciences). mAb were administered 
by i.p. injections. Cetuximab was given i.p. at 200 μg per injection, and 
anti-CD137 mAb was given i.p. at 150 μg per injection at various times 
after tumor inoculation. To determine the efficacy against KRAS-WT and 
mutant tumors, nu/nu mice were inoculated with 1 × 106 T84 (KRAS-WT) 
tumor cells or 1 × 106 HCT116 (KRAS G13D mutant) tumor cells s.c. on 
the left flank. To determine the immune cell subsets necessary for efficacy, 
BALB/c mice were inoculated with 1 × 106 TUBO-EGFR tumor cells s.c. on 
the left flank. Cetuximab and anti-CD137 mAb were administered after 
tumor inoculation as above. To characterize the adaptive immune response 
following combination therapy, BALB/c mice were inoculated with 1 × 106 
TUBO-EGFR tumor cells s.c. on the left flank and 1 × 106 TUBO-EGFR 
tumor cells s.c. on the right flank. Cetuximab and anti-CD137 mAb were 
administered after tumor inoculation as above. Tumor growth was mea-
sured by caliper twice a week and expressed as the product of length by 
width in square centimeters. Mice were sacrificed when tumor size reached 
4 cm2 or when tumor sites ulcerated. All in vivo models were piloted with 
5 mice per group and repeated with 10 mice per group, except in the 
2-tumor model, in which 15 mice were inoculated and 5 per group sacri-
ficed on day 24 for tumor-infiltrating lymphocyte analysis and peripheral 
blood collection for assessment of CD8+ T cell function ex vivo.
Adoptive immunity transfer experiments (Winn assay). BALB/c mice were inoc-
ulated with 1 × 106 TUBO-EGFR tumor cells s.c. on the left flank and treat-
ed with either cetuximab monotherapy on days 14, 21, 28, and 35 or sequen-
tial cetuximab and anti-CD137 mAb combination with cetuximab dosed as 
in the monotherapy group and anti-CD137 mAb on the subsequent day. 
All mice were sacrificed 50 days after being inoculated with tumor cells. 
Total or CD8-selected suspensions were prepared by CD8a+ T cell Isolation 
Kit (Miltenyi Biotec GmbH) and purification assessed by flow cytometric 
analysis and confirmed as more than 95%. Total or in vitro–purified CD8+ 
splenocytes were admixed with TUBO or TUBO-EGFR tumor cells (100:1 
ratio) and coinjected into naive BALB/c mice. The results were expressed as 
percentage of animals that were tumor-free over time.
Detection of CD137-expressing cells in vivo, tumor-infiltrating immune cells in 
vivo, and IFN-γ production assay ex vivo. Blood was collected from the tail vein, 
anticoagulated with 2 mM EDTA in PBS, then diluted 1:1 with 2% Dextran 
T500 (Pharmacosmos) in PBS and incubated at 37°C for 45 minutes to 
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survival. Comparisons of survival curves were made using the log-rank test. 
Correlation coefficients were calculated for comparison of percentage of 
EGFR+CD8+ T cells and percentage of CD137+ NK cells (data presented 
as mean ± SEM). P < 0.05 was considered significant. For tumor burdens, 
comparisons of means were done by ANOVA.
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and following informed consent from patients in accordance with the Dec-
laration of Helsinki. All animal experiments were approved by the Stanford 
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dance with NIH guidelines.
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